All news

Aurobindo Pharma's Lannett plant gets FDA 'official action indicated' status

Upstox · · AI-summarised by FinFlash

The US Food and Drug Administration has classified the Seymour facility of Lannett Company, a step-down subsidiary of Aurobindo Pharma, as 'official action indicated' following an inspection from August 17 to 21, 2026. The FDA issued four observations, and the company said it responded within the required timeline. An OAI status signals the regulator found objectionable conditions and may take regulatory or enforcement action, which can delay approvals from the site.

So What?

The OAI classification is a negative for Aurobindo's US generics pipeline tied to the Lannett site; watch for any warning letter or approval delays.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.